Filter Results:
- Full text PDF available (129)
Publication Year
2002
2018
- This year (11)
- Last 5 years (114)
- Last 10 years (225)
Publication Type
Co-author
Journals and Conferences
Learn More
- Jake E. Delmore, Ghayas C. Issa, +21 authors Constantine Mitsiades
- Cell
- 2011
MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to modulate the function of the c-Myc oncoprotein do not exist. Toward this objective, we have targeted MYC… (More)
- MarÃa Yáñez-Mó, Pia R.-M. Siljander, +57 authors Olivier De Wever
- Journal of extracellular vesicles
- 2015
In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer… (More)
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
- Yazan Alsayed, H. X. Ngo, +20 authors Irene M Ghobrial
- Blood
- 2007
The mechanisms by which multiple myeloma (MM) cells migrate and home to the bone marrow are not well understood. In this study, we sought to determine the effect of the chemokine SDF-1 (CXCL12) and… (More)
- Aldo M Roccaro, Antonio Sacco, +10 authors Irene M Ghobrial
- The Journal of clinical investigation
- 2013
BM mesenchymal stromal cells (BM-MSCs) support multiple myeloma (MM) cell growth, but little is known about the putative mechanisms by which the BM microenvironment plays an oncogenic role in this… (More)
- Aldo M Roccaro, Antonio Sacco, +13 authors Irene M Ghobrial
- Blood
- 2009
Detailed genomic studies have shown that cytogenetic abnormalities contribute to multiple myeloma (MM) pathogenesis and disease progression. Nevertheless, little is known about the characteristics of… (More)
- Paul G Richardson, Edie Weller, +22 authors Kenneth C. Anderson
- Blood
- 2010
This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients (N = 66) received 3-week cycles (n = 8) of bortezomib 1.0 or 1.3… (More)
- Steven P Treon, Leukothea Ioakimidis, +13 authors Irene M Ghobrial
- Journal of clinical oncology : official journal…
- 2009
PURPOSE
We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenström macroglobulinemia (WM).
PATIENTS AND METHODS
A cycle of… (More)
- Thomas E Witzig, Craig B. Reeder, +9 authors Thomas Matthew Habermann
- Leukemia
- 2011
The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL). Everolimus is an oral agent that targets… (More)
- Rao H. Prabhala, Dheeraj Pelluru, +13 authors Nikhil C. Munshi
- Blood
- 2010
Elevated cytokines in bone marrow (BM) micro-environment (interleukin-6 [IL-6], transforming growth factor-beta [TGF-beta], and IL-1beta) may play an important role in observed immune dysfunction in… (More)
- Barbara C. M. Potts, Maher Albitar, +26 authors Michael A Palladino
- Current cancer drug targets
- 2011
The proteasome has emerged as an important clinically relevant target for the treatment of hematologic malignancies. Since the Food and Drug Administration approved the first-in-class proteasome… (More)